RecruitingNCT03848052

Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Lung Cancer in France Since 2015


Sponsor

UNICANCER

Enrollment

70,000 participants

Start Date

Oct 2, 2017

Study Type

OBSERVATIONAL

Conditions

Summary

This database compiles data from existing data available from patient's electronic medical records (EMR) at the 38 participating hospitals (20 French comprehensive cancer centers and 18 public hospitals).


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Adult (over 18)
  • Treated (with radiotherapy or systemic anti-cancer treatment) for a lung cancer or diagnosed with metastatic lung cancer over the selection period at one of the participating site

Exclusion Criteria1

  • \- None

Locations(21)

Institut de Cancérologie de l'Ouest - Paul Papin

Angers, France

Institut Bergonié

Bordeaux, France

Centre François Baclesse

Caen, France

Centre Jean Perrin

Clermont-Ferrand, France

Hôpital Intercommunal de Créteil

Créteil, France

Centre Georges-François Leclerc

Dijon, France

Centre Oscar Lambret

Lille, France

Centre Léon Bérard

Lyon, France

Institut Paoli-Calmettes

Marseille, France

Institut régional du Cancer Montpellier / Val d'Aurelle

Montpellier, France

Groupe Hospitalier Région Mulhouse et Sud Alsace - Hôpital Emile Muller

Mulhouse, France

Institut de cancérologie de l'Ouest - René Gauducheau

Nantes, France

Centre Antoine Lacassagne

Nice, France

Institut Curie

Paris, France

Institut Jean Godinot

Reims, France

Centre Henri Becquerel

Rouen, France

Institut Curie - Hôpital René Huguenin

Saint-Cloud, France

Centre Paul Strauss

Strasbourg, France

Institut Claudius Regaud

Toulouse, France

Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, France

Institut Gustave Roussy

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03848052


Related Trials